Souvie Biodelivery

Executive Summary

Souvie Biodelivery is a preclinical-stage biotechnology company developing engineered exosomes for targeted delivery of active pharmaceutical ingredients (APIs). Founded in 2021 and based in Cambridge, Massachusetts, the company leverages exosome biology to enhance biocompatibility, reduce immunogenicity, and protect APIs from degradation. Its platform aims to improve specificity and efficacy, potentially eliminating adverse drug reactions common with conventional delivery systems. By enabling tissue- and site-specific delivery, Souvie addresses key limitations in drug delivery, including off-target toxicity and poor bioavailability. Though still early-stage with no disclosed funding or valuation, the company's technology aligns with the rapidly growing exosome therapeutics field, which has attracted significant interest from pharma and investors. Key challenges include demonstrating in vivo proof-of-concept, scaling manufacturing, and navigating regulatory pathways. Souvie's platform has the potential to transform drug delivery across multiple therapeutic areas, but execution remains unproven at this stage.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data Release40% success
• H1 2027Series A Funding Round50% success
• H2 2027Strategic Partnership with Pharma30% success